Source:http://linkedlifedata.com/resource/pubmed/id/10431768
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1999-9-14
|
pubmed:abstractText |
We investigated whether interferon-beta1a modifies the course of new enhancing lesions in relapsing-remitting multiple sclerosis. Sixty-eight patients were studied by monthly magnetic resonance imaging (MRI) in a pretest-posttest design including 6 months of observation and 6 months of treatment. We examined the course of new Gd-enhancing lesions on two consecutive scans during observation and during treatment. Lesions detected during treatment were also analyzed by MRI 1 year later for persistence of enhancement, persistence of T2 hyperintensity, development of T1 hypointensity, or disappearance. Among the enhancing lesions detected by observation and treatment MRI, respectively, Gd-enhancement persisted at 2 months in 20% and 3% (P < 0.001), T2 hyperintensity persisted in 86% and 63% (P < 0.03), and T1 hypointensity developed in 49% and 15% (P < 0.01). Progression to T1 hypointensity was significantly more frequent in larger lesions during both the observation and treatment periods (P < 0.01). No reenhancement of plaques was present at 1-year follow-up; a further reduction in T2 hyperintensity (63% vs. 39%) was observed while T1 hypointensity remained unchanged. Both the duration of Gd enhancement and the short-term MRI course of new enhancing lesions benefited by treatment with recombinant interferon-beta1a treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0340-5354
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
246
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
443-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10431768-Adjuvants, Immunologic,
pubmed-meshheading:10431768-Adult,
pubmed-meshheading:10431768-Brain,
pubmed-meshheading:10431768-Female,
pubmed-meshheading:10431768-Humans,
pubmed-meshheading:10431768-Interferon-beta,
pubmed-meshheading:10431768-Magnetic Resonance Imaging,
pubmed-meshheading:10431768-Male,
pubmed-meshheading:10431768-Multiple Sclerosis,
pubmed-meshheading:10431768-Observer Variation,
pubmed-meshheading:10431768-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a.
|
pubmed:affiliation |
Department of Neurology, University of Rome La Sapienza, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|